A Fabarius

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure
    Alice Fabarius
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Ruprecht Karls Universität Heidelberg, Mannheim, Germany
    Haematologica 92:834-7. 2007
  2. ncbi Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib
    Alice Fabarius
    III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Wiesbadener Strasse 7 11, 68305 Mannheim, Germany
    Haematologica 93:1145-54. 2008
  3. ncbi Induction of centrosome and chromosome aberrations by imatinib in vitro
    A Fabarius
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Ruprecht Karls Universität Heidelberg, Mannheim, Germany
    Leukemia 19:1573-8. 2005
  4. ncbi Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability
    Alice Fabarius
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Br J Haematol 138:369-73. 2007
  5. ncbi Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells
    M Giehl
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Leukemia 21:1971-6. 2007
  6. ncbi Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients
    O Frank
    III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Universitätsklinikum Mannheim der Ruprecht Karls Universität Heidelberg, Mannheim, Germany
    Leukemia 20:1400-7. 2006
  7. ncbi Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability
    M Giehl
    Medical Clinic III, Faculty for Clinical Medicine Mannheim of University Heidelberg, Mannheim, Germany
    Leukemia 19:1192-7. 2005
  8. ncbi Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
    B Hanfstein
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Leukemia 26:2096-102. 2012
  9. ncbi Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis
    C Zheng
    , , Mannheim, Germany
    Leukemia 20:1028-34. 2006
  10. ncbi Variable transcriptional activity of endogenous retroviruses in human breast cancer
    Oliver Frank
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Strasse 7 11, D 68305 Mannheim, Germany
    J Virol 82:1808-18. 2008

Collaborators

Detail Information

Publications21

  1. ncbi Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure
    Alice Fabarius
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Ruprecht Karls Universität Heidelberg, Mannheim, Germany
    Haematologica 92:834-7. 2007
    ..Seventy-one patients treated with dasatinib after imatinib failure for a median of nine months were evaluated. Novel aberrations within Ph positive and negative clones appeared in six and three patients, respectively...
  2. ncbi Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib
    Alice Fabarius
    III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Wiesbadener Strasse 7 11, 68305 Mannheim, Germany
    Haematologica 93:1145-54. 2008
    ..Dasatinib is a multitargeted inhibitor of ABL, the SRC family, and other tyrosine kinases. We sought to evaluate the effects of this drug on cell proliferation, centrosomes, mitotic spindles, and cell cycle progression in vitro and in vivo...
  3. ncbi Induction of centrosome and chromosome aberrations by imatinib in vitro
    A Fabarius
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Ruprecht Karls Universität Heidelberg, Mannheim, Germany
    Leukemia 19:1573-8. 2005
    ....
  4. ncbi Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability
    Alice Fabarius
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Br J Haematol 138:369-73. 2007
    ..Our data suggest that distinct tyrosine kinases likewise targeted by both drugs are essential actuators in maintenance of centrosome and karyotype integrity...
  5. ncbi Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells
    M Giehl
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Leukemia 21:1971-6. 2007
    ....
  6. ncbi Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients
    O Frank
    III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Universitätsklinikum Mannheim der Ruprecht Karls Universität Heidelberg, Mannheim, Germany
    Leukemia 20:1400-7. 2006
    ..The resulting expression signature point to involvement of BCR-ABL-independent mechanisms of resistance...
  7. ncbi Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability
    M Giehl
    Medical Clinic III, Faculty for Clinical Medicine Mannheim of University Heidelberg, Mannheim, Germany
    Leukemia 19:1192-7. 2005
    ..They may be considered as the driving force of disease progression and could serve as future prognostic markers...
  8. ncbi Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
    B Hanfstein
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Leukemia 26:2096-102. 2012
    ..001) and correspondingly >0% Ph+ (34% of pts; 5-year OS: 91%) compared with 0% Ph+ (66% of pts; 5-year OS: 97%; P=0.015). Treatment optimization is recommended for pts missing these landmarks...
  9. ncbi Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis
    C Zheng
    , , Mannheim, Germany
    Leukemia 20:1028-34. 2006
    ..Our data suggest the existence of a common gene expression profile of CML-BP and provide new insight into the molecular phenotype of blasts associated with disease progression and high malignancy...
  10. ncbi Variable transcriptional activity of endogenous retroviruses in human breast cancer
    Oliver Frank
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Strasse 7 11, D 68305 Mannheim, Germany
    J Virol 82:1808-18. 2008
    ..No evidence for MMTV or human MMTV-like virus transcripts was found, indicating that transcriptionally active, MMTV analogous, exogenous viruses were not present in the breast cancer samples analyzed...
  11. ncbi Smoking increases transcription of human endogenous retroviruses in a newly established in vitro cell model and in normal urothelium
    Ute Gabriel
    Department of Urology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany
    AIDS Res Hum Retroviruses 26:883-8. 2010
    ..Equally, activity measured in human urothelium supported an increase of HERV transcription in current smokers (n = 9) compared to never smokers (n = 4)...
  12. ncbi Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors
    Michelle Giehl
    III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Eur J Haematol 85:139-48. 2010
    ..Despite good response and acceptable tolerability, little is known concerning long-term toxicity. Furthermore, the influence of these inhibitors on disease-unrelated cells is not investigated yet...
  13. ncbi Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study
    Georgia Metzgeroth
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Br J Haematol 143:707-15. 2008
    ..These data confirmed the long-term efficacy of imatinib for PDGFR-rearranged CEL patients, and also showed that a minority of HES cases without known molecular aberrations may benefit from imatinib...
  14. ncbi Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene
    Christoph Walz
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Str 7 11 68305 Mannheim, Germany
    Haematologica 92:163-9. 2007
    ....
  15. ncbi Specific clones of spontaneously evolving karyotypes generate individuality of cancers
    Alice Fabarius
    III Medizinische Klinik Mannheim of the University of Heidelberg at Mannheim, Wiesbadener Str 7 11, 68305 Mannheim, Germany
    Cancer Genet Cytogenet 180:89-99. 2008
    ..This answers the age-old question, why even cancers of the same kind do not have consistent karyotypes...
  16. ncbi Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy
    Alice Fabarius
    III Medizinische Klinik Mannheim, University of Heidelberg at Mannheim, 68305 Mannheim, Germany
    Cancer Genet Cytogenet 143:59-72. 2003
    ....
  17. ncbi DNA microarray-based detection and identification of fungal pathogens in clinical samples from neutropenic patients
    Birgit Spiess
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Theodor Kutzer Ufer 1 3, D 68167, Mannheim, Germany
    J Clin Microbiol 45:3743-53. 2007
    ..The assay detected genomic DNA from 14 fungal pathogens from the clinical samples, pointing to a high significance for improving the diagnosis of IFI...
  18. ncbi Specific aneusomies in Chinese hamster cells at different stages of neoplastic transformation, initiated by nitrosomethylurea
    Alice Fabarius
    III Medizinische Klinik Mannheim, University of Heidelberg, Wiesbadener Strasse 7-11, 68305 Mannheim, Germany
    Proc Natl Acad Sci U S A 99:6778-83. 2002
    ..We conclude that specific aneusomies are necessary for carcinogenesis...
  19. ncbi The chromosomal basis of cancer
    Peter Duesberg
    Department of Molecular and Cell Biology, Donner Laboratory, UC Berkeley, Berkeley, CA 94720, USA
    Cell Oncol 27:293-318. 2005
    ....
  20. ncbi Cancer drug resistance: the central role of the karyotype
    Peter Duesberg
    Dept Mol and Cell Biol, Donner Laboratory, UC Berkeley, Berkeley, CA 94720, USA
    Drug Resist Updat 10:51-8. 2007
    ..We also adduce evidence that resistance of chronic myeloid leukemia against the drug imatinib is chromosomal, although it is widely believed to be due to mutation of a kinase...
  21. ncbi Aneuploidy and cancer: from correlation to causation
    Peter Duesberg
    Department of Molecular and Cellular Biology, Donner Laboratory, UC Berkeley, Berkeley, Calif, USA
    Contrib Microbiol 13:16-44. 2006
    ..Based on this article a similar one, entitled 'The chromosomal basis of cancer', has since been published by us in Cellular Oncology 2005;27:293-318...